262,500 Shares in Zai Lab Limited Unsponsored ADR $ZLAB Bought by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board acquired 262,500 shares of Zai Lab Limited, valued at approximately $9.49 million, representing about 0.24% ownership as of the latest SEC filing.
• Zai Lab recently reported a quarterly loss of $0.37 EPS and revenue of $109.98 million, falling short of analyst expectations of $125.66 million.
• Investment analysts have a moderate buy consensus rating on Zai Lab, with price targets ranging from $52.00 to $75.00, indicating potential upside for investors.

Canada Pension Plan Investment Board purchased a new position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 262,500 shares of the company's stock, valued at approximately $9,487,000. Canada Pension Plan Investment Board owned 0.24% of Zai Lab at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab during the 4th quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd acquired a new position in Zai Lab during the 1st quarter worth approximately $75,000. Barclays PLC increased its position in Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after purchasing an additional 2,856 shares in the last quarter. Advisors Preferred LLC acquired a new position in Zai Lab during the 1st quarter worth approximately $110,000. Finally, Palumbo Wealth Management LLC acquired a new position in Zai Lab during the 1st quarter worth approximately $203,000. Institutional investors own 41.65% of the company's stock.

Insider Buying and Selling at Zai Lab

In related news, insider Rafael Amado sold 3,000 shares of Zai Lab stock in a transaction on Friday, August 8th. The shares were sold at an average price of $35.00, for a total transaction of $105,000.00. Following the completion of the transaction, the insider owned 42,178 shares of the company's stock, valued at $1,476,230. This trade represents a 6.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction on Friday, August 8th. The stock was sold at an average price of $34.74, for a total transaction of $1,737,000.00. Following the transaction, the chief executive officer directly owned 536,962 shares of the company's stock, valued at $18,654,059.88. This represents a 8.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 215,710 shares of company stock valued at $7,589,684 over the last three months. 4.96% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on ZLAB. Jefferies Financial Group began coverage on shares of Zai Lab in a research report on Monday, August 25th. They set a "buy" rating and a $52.00 price objective for the company. Citigroup reiterated a "buy" rating and set a $69.00 price objective (up from $66.00) on shares of Zai Lab in a research report on Monday, August 11th. Leerink Partners set a $75.00 price objective on shares of Zai Lab and gave the stock an "outperform" rating in a research report on Monday, June 30th. Finally, Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $56.35.

Zai Lab Stock Up 2.5%

NASDAQ ZLAB traded up $0.76 on Friday, hitting $30.76. The company's stock had a trading volume of 925,957 shares, compared to its average volume of 489,351. Zai Lab Limited Unsponsored ADR has a 1-year low of $19.16 and a 1-year high of $44.34. The company's 50-day moving average is $35.22 and its 200 day moving average is $34.07. The firm has a market cap of $3.44 billion, a PE ratio of -15.08 and a beta of 1.04.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The firm had revenue of $109.98 million during the quarter, compared to analysts' expectations of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. On average, equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.